← FDA DRUG APPROVALS

FDA NDA · NDA211911

DURYSTA

bimatoprost

Sponsor: ABBVIE

APPLICATION
NDA211911
TYPE
NDA
ORIGINAL APPROVAL
2020-03-04
LATEST ACTION
2024-10-10
ROUTE
INTRACAMERAL, OPHTHALMIC
DOSAGE FORM
IMPLANT
MARKETING STATUS
Prescription

Products

DURYSTA · ReferencePrescription
BIMATOPROST 10MCG · IMPLANT · OPHTHALMIC

Approval history

2024-10-10Labeling · Supplement 2 · standard — Label ↗AP
2020-11-03Labeling · Supplement 1 · standard — Label ↗AP
2020-03-04Type 3 - New Dosage Form · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →